Fig. 2: The specific activity of OXPHOS inhibitors tested in the clinic in leukaemia.
From: Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia
Representation of mechanism of action of each compound and their clinical trial status (Table 1). (GLS: glutaminase; IDH2: isocitrate dehydrogenase; mtDNA: mitochondrial DNA; mtRibosomes: mitochondrial ribosomes; PDH: pyruvate dehydrogenase).
